Nicola Personeni

Researcher
Oncology

Assistant at Humanitas Cancer Center, Humanitas Research Hospital, Milan

Phone +390282244516
Website humanitas.it/medici/nicola-personeni;
E-mail nicola.personeni@hunimed.eu

Academic Background and Education

  • 2008 – today: Assistant in Medical Oncology, Humanitas Cancer Center, Humanitas Research Hospital
  • 2005-2008: Clinical research fellow, Gastrointestinal Oncology Unit, Gasthuisberg University Hospital, Katholieke Universiteit Leuven, Belgium (Prof. Eric Van Cutsem, MD, PhD; Prof. Sabine Tejpar, MD, PhD)
  • 2003-2005: Clinical research fellow, Translational Research Unit, Université Libre de Bruxelles – Institut Jules Bordet, Brussels, Belgium (Prof. Martine Piccart, MD, PhD)
  • 2004: Residency, Oncology, Università degli Studi di Parma
  • 2000: M.D. Degree, Università degli Studi di Milano
  • 2000: Research Fellow, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA (Prof. Michael Caligiuri, MD)

Scientific and Research Interests

Main scientific interests lie in the hepatobiliary area, which is weekly reviewed on clinical grounds within an Institutional Hepatobiliary Tumor Board at Humanitas Clinical and Research Hospital. Taking advantage from such multidisciplinary approach, where different experts of the hepatobiliary field intervene, Dr Personeni current directions for translational research principally involve hepatocellular carcinoma (predictive markers and prognosis) and biliary tract cancers. Consistent with previous experience gained at Gasthuisberg University Hospital (Leuven, Belgium), other area of interest center on colorectal cancer.

Part of the studies have been performed thanks to an expedite access to clinical and molecular data of patients enrolled in several trials for advanced hepatocellular carcinoma and cholangiocarcinoma, which are the result of fruitful international Academia-pharma partnerships.

These works are the starting point for a long-term research goal of dissecting the molecular heterogeneity of hepatobiliary cancers, with special regard to outcomes achieved with different treatment strategies now rapidly making their way into the clinical scenario.

 

Selected publications

  1. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. Clinical usefulness of EGFR Gene Copy Number As a Predictive Marker in Advanced Colorectal Cancer Patients Treated With Cetuximab: A Fluorescent In Situ Hybridization Study. Clin Cancer Res. 2008 Sep 15;14(18):5869-76.
  2. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P. Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. J Clin Oncol. 2010 Aug 10;28(23):3687-94.
  3. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. Usefulness of Alpha-fetoprotein Response in Patients Treated with Sorafenib for Advanced Hepatocellular Carcinoma. J Hepatol. 2012 Jul;57(1):101-7.
  4. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013 Jan;14(1):55-63.
  5. Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz B, Santoro A, Rimassa L. Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget. 2017 Feb 28;8(9):14408-14415.

Full list of publications.

 

Academic honors, awards and prizes

  • 2002: Scholarship “Dottori Ferri” (Ordine dei Medici di Bergamo)
  • 2004: FECS/AACR/ASCO Workshop on “Methods in Clinical Cancer Research”, Flims, Switzerland (fecs.be)
  • 2006: European Society of Medical Oncology (ESMO) grant recipient
  • 2007: Merit Award Recipient American Society of Clinical Oncology
  • 2008: Merit Award Recipient American Society of Clinical Oncology
  • 2008: Premio Ricerca e Internazionalizzazione – Programma Operativo Regione Lombardia ob. 3 Fondo Sociale Europeo 2000-2006 – Misura D3 “Sviluppo e consolidamento dell’imprenditorialità con priorità ai nuovi bacini d’impiego” e Misura D4 “Miglioramento delle risorse umane nel settore della Ricerca e Sviluppo Tecnologico” POR 2000-2006. BURL 42 del 15/10/2008; decreto n. 883 del 03/12/2008.

 

Why
Humanitas
University?
An Established Institution

An Established Institution
Humanitas is a renowned healthcare institution that has offered Medical Degrees for well over a decade as a partner of the University of Milan.

An International Career

An International Career
Join our international medical community where classes are taught in English by experienced professors and medical doctors from around the world. Your degree will allow you to work as a MD in the EU and abroad.

Clinical Experience

Clinical Experience
Direct clinical experience is supported by a solid tutoring system and starts in your third year, which gives you considerable practical experience.

Innovative and Active Teaching

Innovative and Active Teaching
Humanitas curriculum is enhanced by a wide variety of active learning methods based on a student-centred approach (Problem-Based Learning, Case method, Concept maps, Simulated patients).

Milano and Italy

Milano and Italy
Enjoy the style, culture, gastronomy and entertainment of one of Europe's most exciting cities. Venture further to experience the delights of Italy or use the opportunity to learn Italian.

Advanced Research and Technology

Advanced Research and Technology
Humanitas can count on state-of-the-art technologies and research experience. A new simulation centre of 1000 sm, designed according to the highest technological standards, will be ready for autumn 2017.

Contact Us

Contact
Humanitas University
Via Rita Levi Montalcini 4,
Pieve Emanuele 20090 Milan, Italy

To receive our updates subscribe here: Newsletter.

How to Reach Us
From Malpensa Airport

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From Linate Airport

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From Central station

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From the city center

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.

From the highway

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.

By public transport

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.